The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with wild-type KRAS exon2 metastatic colorectal cancer previously treated with bevacizumab within 6 months.
 
Kaori Hayashi
No Relationships to Disclose
 
Seiichiro Mitani
No Relationships to Disclose
 
Hiroya Taniguchi
Honoraria - Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda
Research Funding - Boehringer Ingelheim (Inst); MSD Oncology (Inst); Otsuka (Inst)
 
Satoshi Hamauchi
No Relationships to Disclose
 
Keiji Sugiyama
No Relationships to Disclose
 
Takahiro Tsushima
Honoraria - Chugai Pharma; Taiho Pharmaceutical; Takeda
 
Kazunori Honda
No Relationships to Disclose
 
Akiko Todaka
No Relationships to Disclose
 
Toshiki Masuishi
Honoraria - Chugai Pharma; Merck Serono; Takeda; Yakult Pharmaceutical
 
Tomoya Yokota
No Relationships to Disclose
 
Yukiya Narita
No Relationships to Disclose
 
Nozomu Machida
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Chugai Pharma; Lilly; Merck Serono; Yakult Pharmaceutical
Research Funding - Lilly; Taiho Pharmaceutical
 
Akira Fukutomi
No Relationships to Disclose
 
Takashi Ura
No Relationships to Disclose
 
Yusuke Onozawa
No Relationships to Disclose
 
Masashi Ando
No Relationships to Disclose
 
Hirofumi Yasui
No Relationships to Disclose
 
Kei Muro
Honoraria - Chugai Pharma; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Kentaro Yamazaki
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Lilly; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha
Research Funding - Bristol-Myers Squibb Japan (Inst); Sanofi (Inst)